Year in Review | Published:

Paediatric rheumatology in 2014

Digging deeper for greater precision and more impact in JIA

Nature Reviews Rheumatology volume 11, pages 7072 (2015) | Download Citation

Optimizing the management of childhood arthritis requires detailed knowledge of the disease in an individual patient. Advances in 2014 show how in-depth genetic studies and insights into immunopathogenesis could translate into clinical biomarkers and, eventually, individualized therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Mutation of LACC1 is associated with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. .

  2. 2.

    et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann. Rheum. Dis. .

  3. 3.

    et al. Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity. Nat. Commun. 5, 4593 (2014).

  4. 4.

    , & Juvenile idiopathic arthritis. Lancet 377, 2138–2149 (2011).

  5. 5.

    et al. Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum. 62, 2525–2529 (2010).

  6. 6.

    , & Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat. Rev. Rheumatol. 7, 416–426 (2011).

  7. 7.

    & Update on research and clinical translation on specific clinical areas: from bench to bedside: how insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis. Best Pract. Res. Clin. Rheumatol. 28, 229–246 (2014).

  8. 8.

    et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266–1273 (2010).

  9. 9.

    et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J. Immunol. 193, 2699–2708 (2014).

  10. 10.

    , , , & Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study. Arthritis Rheumatol. 66, 462–469 (2014).

Download references

Acknowledgements

B.P. is supported by EUTRAIN (the 7th Framework programme of the EU), Marie Curie, Network for Initial Training (ITN) grant agreement No 289903, and by the Dutch Arthritis Foundation and the Understanding Childhood Arthritis Network (UCAN-U).

Author information

Affiliations

  1. Department of Paediatric Immunology & Laboratory for Translational Immunology, University Medical Centre Utrecht, PO Box 85090, 3508 AB Utrecht, Netherlands.

    • Berent Prakken
  2. Department of Paediatrics, University of Genova, IRCCS G. Gaslini, Largo G. Gaslini 5, 16147 Genova, Italy.

    • Alberto Martini

Authors

  1. Search for Berent Prakken in:

  2. Search for Alberto Martini in:

Competing interests

B.P. has received speaker fees and/or has served as independent advisor for Amgen, Danone Research and Novo Nordisk. A.M. has in the past 3 years received honoraria and speakers' bureau fees from AstraZeneca, BMS, Boehringer Ingelheim, GSK, MedImmune, Novartis, Novo Nordisk and Sanofi Aventis; the GASLINI Hospital, of which A.M. is a full-time employee, has received support for the research activities of PRINTO from Abbott, AstraZeneca, Bristol–Myers Squibb, Eli Lilly and Company, 'Francesco Angelini' Foundation, GSK, Italfarmaco, Janssen Biologics B.V., Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma and Wyeth Pharmaceuticals.

Corresponding author

Correspondence to Berent Prakken.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2014.224

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing